$55.22
0.320.58%
At Close: -
$55.22
00.00%
After Hours: 5:08 PM EDT
15 minutes delayed
Comments
Loading...
Inari Medical
NARINASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Inari Medical (NASDAQ:NARI) Stock, Analyst Ratings, Price Targets, Forecasts
Inari Medical Inc has a consensus price target of $77.6 based on the ratings of 11 analysts. The high is $97 issued by BTIG on October 17, 2022. The low is $50 issued by Piper Sandler on May 1, 2024. The 3 most-recent analyst ratings were released by Truist Securities, Canaccord Genuity, and Wells Fargo on July 16, 2024, May 1, 2024, and May 1, 2024, respectively. With an average price target of $66.33 between Truist Securities, Canaccord Genuity, and Wells Fargo, there's an implied 20.13% upside for Inari Medical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
Canaccord Genuity
Wells Fargo
Piper Sandler
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Inari Medical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/18/2024 | Buy Now | — | Needham | Mike Matson | — | Downgrade | Buy → Hold | Get Alert |
| 07/16/2024 | Buy Now | 8.66% | Truist Securities | Richard Newitter | $47 → $60 | Maintains | Hold | Get Alert |
| 05/01/2024 | Buy Now | -0.4% | Canaccord Genuity | William Plovanic | $75 → $55 | Maintains | Buy | Get Alert |
| 05/01/2024 | Buy Now | 52.12% | Wells Fargo | Larry Biegelsen | $100 → $84 | Maintains | Overweight | Get Alert |
| 05/01/2024 | Buy Now | -9.45% | Piper Sandler | Adam Maeder | $55 → $50 | Maintains | Neutral | Get Alert |
| 05/01/2024 | Buy Now | 3.22% | Needham | Mike Matson | $72 → $57 | Maintains | Buy | Get Alert |
| 04/12/2024 | Buy Now | 35.82% | Canaccord Genuity | William Plovanic | $75 → $75 | Maintains | Buy | Get Alert |
| 03/22/2024 | Buy Now | -5.83% | Truist Securities | Richard Newitter | $61 → $52 | Maintains | Hold | Get Alert |
| 03/06/2024 | Buy Now | 30.39% | Needham | Mike Matson | → $72 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 30.39% | Needham | Mike Matson | → $72 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 10.47% | Truist Securities | Richard Newitter | $63 → $61 | Reiterates | Hold → Hold | Get Alert |
| 02/29/2024 | Buy Now | -0.4% | Piper Sandler | Adam Maeder | $85 → $55 | Downgrade | Overweight → Neutral | Get Alert |
| 02/29/2024 | Buy Now | 35.82% | Canaccord Genuity | William Plovanic | $79 → $75 | Maintains | Buy | Get Alert |
| 01/23/2024 | Buy Now | 30.39% | Needham | Mike Matson | → $72 | Initiates | → Buy | Get Alert |
| 12/22/2023 | Buy Now | 26.77% | Truist Securities | Richard Newitter | $65 → $70 | Maintains | Hold | Get Alert |
| 11/03/2023 | Buy Now | 17.71% | Truist Securities | Richard Newitter | $60 → $65 | Maintains | Hold | Get Alert |
| 11/02/2023 | Buy Now | 53.93% | Piper Sandler | Adam Maeder | $90 → $85 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | 50.31% | Morgan Stanley | Cecilia Furlong | $83 → $83 | Reiterates | Overweight → Overweight | Get Alert |
| 07/19/2023 | Buy Now | 17.71% | Truist Securities | Richard Newitter | $70 → $65 | Maintains | Hold | Get Alert |
| 07/19/2023 | Buy Now | 43.06% | Baird | David Rescott | → $79 | Initiates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 52.12% | Canaccord Genuity | William Plovanic | $80 → $84 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | 26.77% | Truist Securities | Richard Newitter | $68 → $70 | Maintains | Hold | Get Alert |
| 02/28/2023 | Buy Now | 44.88% | Canaccord Genuity | William Plovanic | $77 → $80 | Maintains | Buy | Get Alert |
| 02/21/2023 | Buy Now | 39.44% | Canaccord Genuity | William Plovanic | $76 → $77 | Maintains | Buy | Get Alert |
| 01/31/2023 | Buy Now | 17.71% | Truist Securities | Richard Newitter | $75 → $65 | Maintains | Hold | Get Alert |
| 01/06/2023 | Buy Now | 50.31% | Morgan Stanley | Cecilia Furlong | $95 → $83 | Maintains | Overweight | Get Alert |
| 12/20/2022 | Buy Now | 35.82% | Truist Securities | Richard Newitter | $84 → $75 | Maintains | Hold | Get Alert |
| 11/03/2022 | Buy Now | 72.04% | Morgan Stanley | Cecilia Furlong | $93 → $95 | Maintains | Overweight | Get Alert |
| 10/17/2022 | Buy Now | 75.66% | BTIG | Marie Thibault | $100 → $97 | Maintains | Buy | Get Alert |
| 10/17/2022 | Buy Now | 44.88% | Truist Securities | Richard Newitter | $87 → $80 | Maintains | Hold | Get Alert |
| 10/12/2022 | Buy Now | 59.36% | Jefferies | Matthew Taylor | → $88 | Initiates | → Buy | Get Alert |
| 09/29/2022 | Buy Now | 53.93% | Berenberg | Dev Weerasuriya | → $85 | Initiates | → Buy | Get Alert |
| 09/16/2022 | Buy Now | 70.23% | Canaccord Genuity | William Plovanic | $92 → $94 | Maintains | Buy | Get Alert |
| 09/13/2022 | Buy Now | 57.55% | Truist Securities | Richard Newitter | → $87 | Initiates | → Hold | Get Alert |
| 07/15/2022 | Buy Now | 68.42% | Morgan Stanley | Cecilia Furlong | $108 → $93 | Maintains | Overweight | Get Alert |
| 06/24/2022 | Buy Now | 81.09% | BTIG | Marie Thibault | $130 → $100 | Maintains | Buy | Get Alert |
| 06/21/2022 | Buy Now | 81.09% | Piper Sandler | Adam Maeder | → $100 | Initiates | → Overweight | Get Alert |
| 03/14/2022 | Buy Now | 73.85% | Canaccord Genuity | William Plovanic | $102 → $96 | Maintains | Buy | Get Alert |
| 02/24/2022 | Buy Now | 95.58% | Morgan Stanley | Cecilia Furlong | $119 → $108 | Maintains | Overweight | Get Alert |
| 02/24/2022 | Buy Now | 72.04% | SVB Leerink | Danielle Antalffy | $85 → $95 | Maintains | Outperform | Get Alert |
| 11/10/2021 | Buy Now | 117.31% | SVB Leerink | Danielle Antalffy | — | Maintains | Outperform | Get Alert |
| 08/11/2021 | Buy Now | 99.2% | SVB Leerink | Danielle Antalffy | — | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Inari Medical (NARI) stock?
The latest price target for Inari Medical (NASDAQ:NARI) was reported by Needham on July 18, 2024. The analyst firm set a price target for $0.00 expecting NARI to fall to within 12 months (a possible -100.00% downside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inari Medical (NARI)?
The latest analyst rating for Inari Medical (NASDAQ:NARI) was provided by Needham, and Inari Medical downgraded their hold rating.
When was the last upgrade for Inari Medical (NARI)?
There is no last upgrade for Inari Medical
When was the last downgrade for Inari Medical (NARI)?
The last downgrade for Inari Medical Inc happened on July 18, 2024 when Needham changed their price target from N/A to N/A for Inari Medical Inc.
When is the next analyst rating going to be posted or updated for Inari Medical (NARI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inari Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inari Medical was filed on July 18, 2024 so you should expect the next rating to be made available sometime around July 18, 2025.
Is the Analyst Rating Inari Medical (NARI) correct?
While ratings are subjective and will change, the latest Inari Medical (NARI) rating was a downgraded with a price target of $0.00 to $0.00. The current price Inari Medical (NARI) is trading at is $55.22, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.